Morphiex Biotherapeutics | MBT-001 enhances natural killer (NK) cell function through thrombospondin-1 (TSP-1) signaling.
484
post-template-default,single,single-post,postid-484,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

MBT-001 enhances natural killer (NK) cell function through thrombospondin-1 (TSP-1) signaling.

Our lead drug, MBT-001 was recently featured in Frontiers in Immunology for enhancing NK cells through the CD47-TSP-1 pathway. MBT-001 is the only CD47 treatment modality that inhibits both SIRPa “Don’t eat me” and TSP-1, thereby eliciting the full cancer-killing potential of CD47.

https://www.frontiersin.org/articles/10.3389/fimmu.2018.02985/full



Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn